

**Injectable antibiotic sensitivity chart ... : Cefizox ceftizoxime sodium /
Wellcome Foundation Ltd., Fujisawa Pharmaceutical Co. Ltd.**

Contributors

Wellcome Foundation Ltd.
Fujisawa Pharmaceutical Co.

Publication/Creation

Crewe : Wellcome Foundation, 1985.

Persistent URL

<https://wellcomecollection.org/works/rv6vz55f>

License and attribution

Conditions of use: it is possible this item is protected by copyright and/or related rights. You are free to use this item in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s).

**wellcome
collection**


Wellcome Collection
183 Euston Road
London NW1 2BE UK
T +44 (0)20 7611 8722
E library@wellcomecollection.org
<https://wellcomecollection.org>

Injectable Antibiotic Sensitivity Chart

Prescribing Information
Presentation Vials containing 500mg, 1g and 2g of ceftriaxone sodium as the sterile sodium salt.
Uses Broad spectrum bactericidal cephalosporin antibiotic. Indications include lower respiratory tract infections, gonorrhoea, meningitis, osteomyelitis, skin and soft tissue infections. Ceftriaxone is active against a wide range of Gram-positive and Gram-negative organisms and is stable to a broad spectrum of beta-lactamases.
Indications Produced by both aerobic and anaerobic organisms.
Dosage and administration By slow intravenous injection, by continuous or intermittent intravenous infusion, or by deep intramuscular injection. For reconstitution details see Data Sheet. Modification of the following guideline dosages is necessary in patients with impaired renal function (see Data Sheet). Adults: primary biliary infection, 0.5-1g 12-hourly, IM or IV; gonorrhoea, 1g single dose, IM; other infections, 1-2g 8-12 hourly, IM or IV; severe or life-threatening infections, 2-3g 8-hourly, IM or IV. Children: over the age of 3 months, 50-100mg/kg bodyweight/day in 2-4 divided doses, increased in severe or life-threatening infections to 100-150mg/kg bodyweight/day. The total dose should not exceed the adult dose. Under the age of 3 months, insufficient data to recommend use.
Contra-indications Hypersensitivity to cephalosporin antibiotics.
Precautions Renal status should be monitored, especially in seriously ill patients receiving maximum dose therapy and no administration of aminoglycoside antibiotics. Although the occurrence has not been reported with Ceftriaxone, nephrotoxicity has been reported following concomitant administration of other cephalosporins and aminoglycosides. As with any antibiotic, prolonged use may result in overgrowth of non-susceptible organisms. Caution in penicillin-sensitive patients because of possible cross-reaction.
Side and adverse effects Ceftriaxone is generally well tolerated. The most common adverse reactions have been local following IM or IV injection. These include burning, redness, pain, induration, tenderness, paronychia and phlebitis. Other adverse reactions include hypersensitivity reactions (rash, pruritus, fever, gastro-intestinal disturbance, diarrhoea, nausea, and vomiting), vaginitis, transient neutropenia, thrombocytopenia, leucopenia, leucocytosis and thrombocytopenia have been reported. Intra-arterial administration has been associated with phlebitis. Sulfur and sodium metabisulfite have occasionally been observed.
Use in pregnancy and lactation There are no data in pregnant women. Thus the benefit of using Ceftriaxone in pregnancy should be weighed against the possible hazard. Caution should be exercised if Ceftriaxone is administered to a nursing mother.
Basic NHS costs
 1 x 500mg vial (PL310174) £2.76
 1 x 1g vial (PL310175) £5.50
 1 x 2g vial (PL310176) £11.00

Sources used to compile this table
 Chu, K.P. and Neu, H.C. (1983) Antimicrobial Agents and Chemotherapy, 17, 563.
 Garrod, L.P., Lambert, H.P. and O'Grady, F. (1981) Antibiotic and Chemotherapy, 5th Edition, Churchill Livingstone.
 Gaspone, P. et al. (1983) Drug Intelligence and Clinical Pharmacy, 17, 415.
 Kucers, A. and Bennett, N. Mick. (1978) The Use of Antibiotics, 3rd Edition, Hemschen.
 Manufacturer's Literature.
 Neu, H.C. (1983) Reviews of Infectious Diseases, 5, Suppl 2.
 Neu, H.C. (1982) Annals of Internal Medicine, 97, 439-419.
 Neu, H.C. (1981) Antimicrobial Agents and Chemotherapy, 19, 3, 414.
 Shannan, K. et al. (1980) Antimicrobial Agents and Chemotherapy, 18, 2, 292.
 Supplement to Journal of Antimicrobial Chemotherapy.
 Tobramycin, Suppl. A, 14, 1976.
 Mezlocillin, Suppl. 1A, 8, 1982.
 Benzocillin, Suppl. B, 8, 1982.
 Azlocillin, Suppl. B, 11, 1985.
 Cefotaxime, Suppl. A, 2, 1983.
 Ceftriaxone, Suppl. B, 8, 1982.
 Cefuroxime, Suppl. C, 10, 1982.
 Wise, R. (1980) Journal of Antimicrobial Chemotherapy, 6, 5, 595.

MIC ₉₀	CEFIZOX	ceftazidime	latamoxef	cefisulodin	cefotaxime	cefotetan	ceftriaxone	cefuroxime	cefamandole	cefotaxim	cephradine	cephazolin	cephaloridine	cephalothin	gentamicin	tobramycin	amikacin	benzyl penicillin	ampicillin	flucloxacillin/cloxacillin	carbenicillin	piperacillin	ticarcillin	mezlocillin	azlocillin	CEFIZOX
Gram positives																										
Staph. aureus (pyogenes)	2	8	16	4	2	8	31	22	1	3.1	2	1.2	0.12	0.5	0.06	0.25	2	0.03	0.06	0.12	8	8	8	64	8	2
Staph. albus (epidermidis)	8	8	32	8	8	64	50	1	2	12.5		0.8		1	16			0.03	64			16	64	R	16	8
Strep. faecalis (enterococcus)	R	R	R	R	R	R	R	R	R	R	R	R	R	4	8	R		2	1	32	25	8	R	16	4	R
Strep. pyogenes	0.03	0.25	4	2	0.03	2	0.2	0.05	0.07	0.7	0.5	0.1	0.01	0.1	8	16	R	0.007	0.03	0.06	0.15	0.2	1.25	0.025	0.1	0.03
Strep. pneumoniae	0.12	0.25	2	8	0.12	32	0.1	0.03	0.5	1	2	0.1	0.03	0.25	16	32	R	0.015	0.06	0.25	0.15	0.1	1.25	0.025	0.1	0.12
Gram negatives																										
H. influenzae	0.03	0.12	0.06	32	0.03	4	0.1	2	1	5.9	32	9.8	16	9.4	0.5	0.5	2	1	0.25	16	0.5	0.1	0.12	0.06	0.06	0.03
E. coli	0.25	0.5	0.25	R	0.25	0.5	0.1	5	4	8.2	16	5	4	5	2	1	2	64	8	R	32	32	32	16	128	0.25
Klebsiella pneumoniae	0.03	0.25	0.25	R	0.12	0.25	0.1	3.5	8	5.1	16	5.8	4	32	1	1	1	100	16	R	R	16	R	64	64	0.03
Enterobacter aerogenes	0.12	0.2	0.2	R	0.25	32	0.2	8	8	R	R	R	R	R	1	4	2	R	R	R	64	64	64	16	R	0.12
Proteus mirabilis	0.1	0.2	0.2	R	0.1	0.25	0.06	1	2	4	16	32	4	64	2	4	4	32	2	R	0.8	1	0.8	1.6	4	0.1
Morganella morganii	0.5	2	0.5	R	2	8	3.1	R	R	8	R	R	R	R	4	2	8	R	R	R	8	64	8	4	R	0.5
Neisseria gonorrhoeae	0.007	0.12	0.06	8	0.015	1	0.025	0.06	0.02	0.25	0.5	0.12	8	0.15	2		32	0.007	0.04	0.5	0.3	0.03	0.2	0.12		0.007
Neisseria meningitidis	0.01	0.01	0.05	8	0.01	1	0.025	0.06	0.125	0.25			1	0.5	2			0.03	0.06	0.5	0.1	0.03		0.03		0.01
Salmonella spp.	0.25	0.25	0.25	R	0.25	0.06	0.05	4	4	4	8	2	2	4	0.25	1	4	4	8	R	32	2	4		8	0.25
Shigella spp.	0.25	0.25	0.25	R	0.25	0.12	0.025	4	R	4			2	8	0.25	2	4	16	8	R	100					0.25
Serratia marcescens	0.12	2	4	R	0.25	2	50	R	R	16	R	R	R	R	2	1	2	R	R	R	64	4	32	8	32	0.12
Providencia spp.	0.015	2	1	R	0.12	1	0.1	R	100	8	R		R	R			3.1	R	R	R						0.015
Enterobacter cloacae	8	8	4	R	8	R	25	12.5	50	R				1	4	2	R							R		8
Citrobacter freundii	8	8	8	R	8	16	0.2	R	R	R				1		2	R		R	R	64	128	16	R	8	
Acinetobacter	25	16	R	R	100	R	>100	100	100	100				R			4	4	R		128	128	64	32		25
Pseudomonas aeruginosa	64	8	32	32	64	R	>100	R	R	R	R	R	R	16	2	16	R	R	R	R	50	6.3	50	25	50	64
Anaerobes																										
Clostridium perfringens	1	16	4		1	16	25	2	2	2				0.5	0.5	R			0.06	0.25	1	32	1		1	1
Peptococcus	2	32	4		2	1	4		4			16										2		2	1	2
Peptostreptococcus	4	8	4		4	2	4		16			16										8		4	8	4
Bacteroides fragilis	32	128	16	R	64	4	>100	R	128	16	R		64	R			R	32	16	32	R	64		64	64	32
Actinomyces spp.	8	64	16		8													0.05			0.5	4		4	4	8



Further information is available on request. The Wellcome Medical Division. Wellcome Fujisawa. Made by Fujisawa Pharmaceutical Co Ltd, Osaka, Japan for the Wellcome Foundation Ltd London.